← Back to patent-cliff list

Ifetroban

Tier C — Watch / trade

Ifetroban

Bristol Myers Squibb
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:TBXA2R

Brand:Boxaban, Portaban, Vasculan, Pepatoren, Dyscorban

Indications (approved):Idiopathic pulmonary fibrosis, Duchenne muscular dystrophy, 扩张型心肌病, Solid tumour, 阿司匹林引起的哮喘, 鼻息肉, 病理过程, 结缔组织疾病

Regional status

US
Phase II
2011-10-01
EU
-
China
-
Japan
-

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 8 · Total yield /
IFET-001404575-34-4IFET-002—IFET-003—IFET-004—IFET-005135682-53-0IFET-006142757-91-3IFET-007147266-42-0IFET-008147266-43-1IFET-009150254-77-6IFET-010142663-84-1API · Ifetroban
CodeCAS No.Intermediate
IFET-001404575-34-4(1S,3aR,4R,7S,7aR)-octahydro-4,7-epoxyisobenzofuran-1-ol
IFET-002-(2-(3-((dimethyl(neopentyl)silyl)oxy)propyl)phenyl)magnesium bromide
IFET-003-(S)-(2-(3-((dimethyl(neopentyl)silyl)oxy)propyl)phenyl)((1S,2S,3R,4R)-3-(hydroxymethyl)-7-oxabicyclo[2.2.1]heptan-2-yl)methanol
IFET-004-((1R,2R,3R,4S)-3-(2-(3-((dimethyl(neopentyl)silyl)oxy)propyl)benzyl)-7-oxabicyclo[2.2.1]heptan-2-yl)methanol
IFET-005135682-53-0methyl 3-(2-(((1S,2R,3R,4R)-3-(hydroxymethyl)-7-oxabicyclo[2.2.1]heptan-2-yl)methyl)phenyl)propanoate
IFET-006142757-91-3(1R,2S,3R,4S)-3-(2-(3-methoxy-3-oxopropyl)benzyl)-7-oxabicyclo[2.2.1]heptane-2-carboxylic acid
IFET-007147266-42-0(S)-2-amino-3-hydroxy-N-pentylpropanamide
IFET-008147266-43-1methyl 3-(2-(((1S,2R,3S,4R)-3-(((S)-3-hydroxy-1-oxo-1-(pentylamino)propan-2-yl)carbamoyl)-7-oxabicyclo[2.2.1]heptan-2-yl)methyl)phenyl)propanoate
IFET-009150254-77-6methyl 3-(2-(((1S,2R,3S,4R)-3-((S)-4-(pentylcarbamoyl)-4,5-dihydrooxazol-2-yl)-7-oxabicyclo[2.2.1]heptan-2-yl)methyl)phenyl)propanoate
IFET-010142663-84-1methyl 3-(2-(((1S,2R,3S,4R)-3-(4-(pentylcarbamoyl)oxazol-2-yl)-7-oxabicyclo[2.2.1]heptan-2-yl)methyl)phenyl)propanoate

Frequently asked questions

What are the approved indications of Ifetroban?

Approved indications include: Idiopathic pulmonary fibrosis, Duchenne muscular dystrophy, 扩张型心肌病, Solid tumour, 阿司匹林引起的哮喘, 鼻息肉, 病理过程, 结缔组织疾病.

When does the Ifetroban patent expire?

No public expiry year is available for Ifetroban yet; this page updates once verified.

How many synthesis routes are recorded for Ifetroban?

1 synthesis routes are recorded; the shortest is 8 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Ifetroban intermediates?

All intermediates in Ifetroban routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Ifetroban intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-19